11/21/2022
Transdermal CBD gel significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane in a dose-dependent manner.
Conclusions
These data indicate that topical CBD application has therapeutic potential for relief of arthritis pain-related behaviours and inflammation without evident side-effects.
Almost 50 million (22.2%) adult Americans over 18 were diagnosed with arthritis in 2007–2009, most prominently osteoarthritis and the autoimmune disease rheumatoid arthritis. A projected increase to 67 million is anticipated by 2030 (Centers for Disease Control and Prevention (CDC), 2010). The most effective treatment for rheumatoid arthritis is injectable fusion-proteins which sequester the most prominent proinflammatory cytokine tumour necrosis factor α (TNFα). These chimeric antibodies may halt progression of the disease, but side-effects include immune suppression (Crawford and Curtis, 2008; Furst, 2010; Hastings et al., 2010). Neurogenic drive also contributes to severity of arthritic inflammation (Sluka et al., 1994), and may contribute to its reoccurrence.
More recently, CBD was successfully delivered transdermally in different species for anti-inflammatory activity (Lodzki et al., 2003; Stinchcomb et al., 2004; Paudel et al., 2010). In this study, in vivo efficacy of transdermal CBD delivery to reduce inflammation and pain-related behaviors is tested in a rat adjuvant-induced monoarthritis model with both inflammatory and neurogenic properties (Sluka et al., 1994).
source:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851925/
https://onlinelibrary.wiley.com/doi/10.1002/ejp.818
D.C. Hammell, L.P. Zhang,, F. Ma, S.M. Abshire, S.L. McIlwrath, A.L. Stinchcomb,1 and K.N. Westlund
Eur J Pain. 2016 Jul; 20(6): 936–948.